* Biomira Inc., of Edmonton, Alberta, received No. 5,798,090, covering enhancing cellular immunity by administering a synthetic conjugate of a carbohydrate epitope and an immunogenic carrier. The company also received a Notice of Allowance for "Process for Preparation of Glycosides of Tumor-Associated Carbohydrate Antigens."

* Bio-Technology General Corp., of Iselin, N.J., received No. 5,783,421, relating to the company's Factorex genetically engineered factor Xa inhibitor agent. Factorex, an anticoagulant, currently is in preclinical studies and should enter clinical trials next year.

* BioTransplant Inc., of Charlestown, Mass., and MedImmune Inc., of Gaithersburg, Md., received No. 5,817,311, relating to the companies' antibodies BTI-322 and MEDI-507, the humanized form of BTI-322. The patent, licensed exclusively to BioTransplant and sublicensed to MedImmune, covers the use of any antibody that binds to the target epitome recognized by the BTI-322 and MEDI-507 antibodies. The BTI-322/MEDI-507 receptor may play a key role in regulating organ rejection, graft versus host disease and various autoimmune diseases.

* Caliper Technologies Corp., of Palo Alto, Calif., received No. 5,800,690, on fundamental elements of microfluidic technology. The patent, "Variable Control of Electroosmotic and Electrophoretic Forces in a Fluid Containing Structure Via Electrical Forces," covers the method for rapidly developing, linking, and controlling diverse laboratory functions on a microchip.

* Cortex Pharmaceuticals Inc., of Irvine, Calif., received No. 5,783,587, "Benzoyl Piperidines/Pyrrolidines for Enhancing Synaptic Response."

* Cypros Pharmaceutical Corp., of Carlsbad, Calif., received a notice of allowance for all claims which broadly cover the use of Cordox in the treatment of sickle cell disease.

* Demegen Inc., of Pittsburgh, Pa., received No. 5,773,413, "Method of Combating Mammalian Neoplasia, and Lytic Peptides Therefore." The claims are directed to treatment of cancers by various routes of administration, with Demegen's proprietary non-naturally occurring amphipathic peptides. The cancers include but are not limited to: prostate, dermal, breast, cervical, ovarian, and uterine neoplasias.

* Energy BioSystems, of The Woodlands, Texas, received two patents: No. 5,804,433, "Rhodococcus Flavin Reductase Complementing DszA and DszC Activity," and No. 5,811,285, "TDszD Utilization in Desulfurization of DBT by Rhodococcus sp. TGTS8." The first provides a novel enzyme that activates an integral portion of the biodesulfurization pathway and increases the desulfurizatin rate. The second describes the enhancement of desulfurization with the addition of complementary enzymes to the biocatalyst system.

No Comments